Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy.
Expert Opin Biol Ther. 2022 Dec;22(12):1475-1487. doi: 10.1080/14712598.2022.2116978. Epub 2022 Aug 25.
Pustular psoriasis (PP) is a rare subtype of psoriasis. Overall, the growing evidence - in particular for acute generalized PP (GPP) - supports that it is a separate entity with a specific pathogenetic pathway. Interleukin (IL)-17/T-helper 17 (Th17) axis involvement may play an important role in the pathophysiology of PP. Biologicals, often required to achieve clinical remission, have changed the treatment of PP.
We provide the reader with an overview of all the available evidence on the use of the antibody-based therapy targeting IL-17A in patients with PP.
Although papers reported in this review do not provide definitive evidence (due to methodological limitations) to support the use of IL-17 inhibitors as potential first-line for the treatment of PP, based on our own experience and according to most of the reported literature, targeting IL-17A, may represent the best therapeutical approach in this peculiar clinical spectrum of psoriasis.
脓疱型银屑病（PP）是一种罕见的银屑病亚型。总的来说，越来越多的证据——特别是针对急性泛发性脓疱型银屑病（GPP）——支持其是一种具有特定发病机制途径的独立实体。白细胞介素（IL）-17/T 辅助 17（Th17）轴的参与可能在 PP 的病理生理学中起重要作用。生物制剂常常需要达到临床缓解，这改变了 PP 的治疗方法。
我们为读者提供了关于针对 PP 患者使用靶向 IL-17A 的抗体疗法的所有现有证据的概述。
尽管本综述中报道的论文由于方法学限制（due to methodological limitations）无法提供确凿的证据来支持将 IL-17 抑制剂作为治疗 PP 的一线药物，但根据我们自己的经验和大多数报道的文献，靶向 IL-17A 可能代表了这种特殊银屑病临床谱中最佳的治疗方法。
